Compare EONR.WS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EON Resources Inc. Warrants each whole warrant exercisable for three quarters of one share of Class A Common Stock at an exercise price of $11.50 per whole share
Current Price
| Metric | EONR.WS | GOVX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.0M |
| IPO Year | N/A | 1996 |
| Metric | EONR.WS | GOVX |
|---|---|---|
| Price | $0.04 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $240.00 |
| AVG Volume (30 Days) | 320.0 | ★ 286.6K |
| Earning Date | N/A | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.07 | $0.11 |
| 52 Week High | $0.07 | $1,002.75 |
| Indicator | EONR.WS | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 55.16 |
| Support Level | N/A | $0.11 |
| Resistance Level | N/A | $3.00 |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | 0.30 |
| Stochastic Oscillator | 0.00 | 62.62 |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.